Powder spray may stop rebleeding after colonoscopy
NCT ID NCT07679139
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether spraying a powder made of tranexamic acid and sucralfate onto bleeding sites in the colon can lower the chance of rebleeding after standard treatment. About 60 people hospitalized for lower GI bleeding will take part. All receive usual care, and half also get the powder spray. Researchers will track rebleeding over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tranexamic acid and sucralfate powder spray
- What this could lead to
- If effective, this simple powder spray could become a standard add-on to reduce rebleeding after colonoscopy for lower GI bleeding.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The powder could cause allergic reactions or other complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients suspect lower gastrointestinal bleeding Exclusion Criteria: * absence of indication for endoscopic hemostasis * known allergy to sucralfate, TXA * presence of a hollow organ perforation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bleeding after gi endoscopy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.